The cancer type may be more specific than it first appears
Two cancers arising in the same organ can come from different cell types. Pathology may identify a subtype that behaves differently or responds to different treatments.
The wording used in ordinary conversation, such as “lung cancer” or “pancreatic cancer”, may therefore hide an important difference in the exact diagnosis.
Stage and location matter
Stage describes the extent of cancer. Treatment for a small cancer confined to its original site can differ from treatment for cancer involving lymph nodes or distant organs.
Location can matter within the same stage. A tumour close to a major blood vessel, airway, bowel or another sensitive structure may require a different surgical or radiotherapy approach from one elsewhere.
Grade and cancer biology matter
Grade provides information about how the cancer looks and is likely to behave. Some cancers also have receptors, proteins or genetic changes that predict whether a particular treatment is likely to help.
These are often called biomarkers or molecular characteristics. The useful tests depend on the cancer. Not every tumour needs every available test, and finding a biomarker does not always mean that an effective targeted treatment exists.
Previous treatment changes the choices
A treatment used before may no longer work, may have caused a lasting side effect, or may limit the safe dose of another treatment. Previous surgery can also change anatomy, and previous radiotherapy affects whether an area can be treated again.
Someone newly diagnosed and someone whose cancer has returned may therefore receive different recommendations even if the pathology name is the same.
Other health conditions and organ function matter
Doctors consider kidney, liver, heart, lung and bone-marrow function; other illnesses; medicines; mobility; frailty; allergies; and the ability to recover from treatment.
Age alone does not decide treatment. The relevant question is whether the likely benefit justifies the risks for that individual.
Performance status adds information about daily function
Performance status describes how illness is affecting activity and self-care. It can help estimate treatment tolerance and benefit, but it is only one part of the assessment and should be interpreted in context.
The treatment aim may differ
Treatment may be intended to cure cancer, reduce the chance of recurrence, control it for as long as possible, or relieve a symptom. The same drug or radiotherapy technique can sometimes be used with different aims, doses or schedules.
Understanding the intended outcome helps make sense of the plan and the trade-offs being discussed.
The MDT considers several specialist viewpoints
In UK cancer care, scans, pathology and treatment options are commonly reviewed at a multidisciplinary team meeting. Surgeons, oncologists, radiologists, pathologists, specialist nurses and others contribute according to the cancer.
The MDT makes a clinical recommendation. It does not replace the discussion with the patient. What happens at a cancer MDT meeting? explains the process.
Personal priorities and preferences matter
There may be more than one reasonable option. People can place different weight on possible benefit, side effects, time in hospital, fertility, work, caring responsibilities, independence or quality of life.
A good decision combines clinical evidence with informed preferences. It should not be based simply on copying another person's treatment.
The plan can change
New scan results, side effects, response to treatment or changes in health can alter the balance. A treatment that was not suitable earlier may become relevant later, and the reverse can also happen.
Questions to ask
- What exact type, stage and grade of cancer do I have?
- Are any biomarkers relevant?
- What is the aim of treatment?
- How do my previous treatment, health and performance status affect the choice?
- What did the MDT recommend, and were other options considered?
- How have my priorities been included?
Another patient's experience can be valuable for support, but it is not a reliable template for treatment. Ask the team to explain the factors that make your plan specific to you.
